Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 25;47(12):e79.
doi: 10.1136/medethics-2020-106504. Online ahead of print.

SARS-CoV-2 challenge studies: ethics and risk minimisation

Susan Bull  1 , Euzebiusz Jamrozik  2 , Ariella Binik  3 , Michael J Parker  4
Affiliations

SARS-CoV-2 challenge studies: ethics and risk minimisation

Susan Bull et al. J Med Ethics. .

Abstract

COVID-19 poses an exceptional threat to global public health and well-being. Recognition of the need to develop effective vaccines at unprecedented speed has led to calls to accelerate research pathways ethically, including by conducting challenge studies (also known as controlled human infection studies (CHIs)) with SARS-CoV-2 (the virus which causes COVID-19). Such research is controversial, with concerns being raised about the social, legal, ethical and clinical implications of infecting healthy volunteers with SARS-CoV-2 for research purposes. Systematic risk evaluations are critical to inform assessments of the ethics of any proposed SARS-CoV-2 CHIs. Such evaluations will necessarily take place within a rapidly changing and at times contested epidemiological landscape, in which differing criteria for the ethical acceptability of research risks have been proposed. This paper critically reviews two such criteria and evaluates whether the use of effective treatment should be a necessary condition for the ethical acceptability of SARS-CoV-2 CHIs, and whether the choice of study sites should be influenced by COVID-19 incidence levels. The paper concludes that ethical evaluations of proposed SARS-CoV-2 CHIs should be informed by rigorous, consultative and holistic approaches to systematic risk assessment.

Keywords: clinical trials; ethics; research ethics; scientific research.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. United Nations . ‘Landmark collaboration’ to make COVID-19 testing and treatment available to all. UN News, 2020.
    1. Plotkin SA, Caplan A. Extraordinary diseases require extraordinary solutions. Vaccine 2020;38(24):3987–8. 10.1016/j.vaccine.2020.04.039 - DOI - PMC - PubMed
    1. Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis 2020;221(11):1752–6. 10.1093/infdis/jiaa152 - DOI - PMC - PubMed
    1. Schaefer GO, Tam CC, Savulescu J, et al. . COVID-19 vaccine development: time to consider SARS-CoV-2 challenge studies? Vaccine 2020;38(33):5085–8. 10.1016/j.vaccine.2020.06.007 - DOI - PMC - PubMed
    1. Jamrozik E, Selgelid M. Human challenge studies in endemic settings ethical and regulatory issues. SpringerBriefs in Ethics, 2020.